ProQR Therapeutics Nominates Board Member, Sets Shareholder Meeting
Ticker: PRQR · Form: 6-K · Filed: Apr 23, 2024 · CIK: 1612940
| Field | Detail |
|---|---|
| Company | Proqr Therapeutics N.V. (PRQR) |
| Form Type | 6-K |
| Filed Date | Apr 23, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, board-nomination, shareholder-meeting
TL;DR
ProQR names new board member, shareholder meeting May 2nd.
AI Summary
ProQR Therapeutics N.V. announced on April 23, 2024, that it has nominated Martin Maier, PhD, to its Board of Directors. The company also announced that its Annual Meeting of Shareholders will be held on May 2, 2024. This filing is a Form 6-K, reporting foreign private issuer information.
Why It Matters
The nomination of a new board member and the scheduling of the annual shareholder meeting are key governance events that can signal strategic direction and provide opportunities for shareholder engagement.
Risk Assessment
Risk Level: low — This filing is a routine corporate announcement regarding board nominations and a shareholder meeting, with no immediate financial or operational risks disclosed.
Key Players & Entities
- ProQR Therapeutics N.V. (company) — Registrant
- Martin Maier, PhD (person) — Nominee to Board of Directors
- May 2, 2024 (date) — Date of Annual Meeting of Shareholders
- April 23, 2024 (date) — Date of Press Release
FAQ
Who is Martin Maier, PhD, and what is his background relevant to ProQR Therapeutics?
The filing does not provide specific details about Martin Maier, PhD's background or qualifications beyond his nomination to the Board of Directors.
What is the purpose of the Annual Meeting of Shareholders on May 2, 2024?
The filing announces the date of the Annual Meeting of Shareholders but does not specify the agenda or purpose of the meeting.
Is this filing related to any financial performance or clinical trial updates for ProQR Therapeutics?
No, this Form 6-K filing is a report of a foreign private issuer and specifically announces a board nomination and the date of the annual shareholder meeting, not financial results or clinical trial data.
What is a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that is required to be filed with the SEC if they are required to disclose or distribute information to their security holders pursuant to the laws of their home country.
Where is ProQR Therapeutics N.V. based?
ProQR Therapeutics N.V. is based in Leiden, The Netherlands.
Filing Stats: 298 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-04-23 07:06:42
Filing Documents
- tm2412402d1_6k.htm (6-K) — 11KB
- tm2412402d1_ex99-1.htm (EX-99.1) — 25KB
- tm2412402d1_ex99-2.htm (EX-99.2) — 34KB
- tm2412402d1_ex99-3.htm (EX-99.3) — 67KB
- tm2412402d1_ex99-4.htm (EX-99.4) — 57KB
- tm2412402d1_ex99-3img004.jpg (GRAPHIC) — 12KB
- tm2412402d1_ex99-3img005.jpg (GRAPHIC) — 5KB
- tm2412402d1_ex99-2img001.jpg (GRAPHIC) — 17KB
- tm2412402d1_ex99-2img002.jpg (GRAPHIC) — 5KB
- 0001104659-24-050316.txt ( ) — 248KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PROQR THERAPEUTICS N.V. Date: April 23, 2024 By: /s/ René Beukema René Beukema Chief Corporate Development Officer and General Counsel INDEX TO EXHIBITS Number Description 99.1 Press Release of ProQR Therapeutics N.V. dated April 23, 2024. 99.2 Notice of the 2024 Annual General Meeting of Shareholders 99.3 Explanatory Notes to the Agenda of the 2024 Annual General Meeting of Shareholders 99.4 Proxy Form